Clinical features and mutation characteristics of the patients with therapy-related leukemia
| Age/ sex . | Primary disease . | Therapy . | Latent period (mo) . | Secondary disease . | Chromosome . | AML1 mutation . | Case no. . |
|---|---|---|---|---|---|---|---|
| 39/F | Astrocytoma | Radiation 124 Gy MCNU, ACNU, CPA, DXR | 152 | MDS (RAEBt) | 46, XX | 530G>A Arg177Gln | 9 |
| 62/M | B-cell lymphoma3-150 | Radiation 39.6 Gy CPA, DXR, VCR, PSL, VP16, MIT | 74 | AML (M0) | 46, XY | 413_414insCGGGGG Gly138_Arg139insGlyGly | 10 |
| 72/F | Uteric cancer | Carboplatin, PSL | 22 | MDS (RAEB) | 45, XX, −5, t(12;21)(q24;q22) | WT | — |
| 56/F | Breast cancer | 5-FU, CPA, MTX | 31 | AML (M3) | 46, XX, t(15;17)(q22;q21) | WT | — |
| 52/F | Breast cancer | Radiation 45 Gy | 18 | AML (M2) | 46, XX, t(8;21)(q22;q22) | WT | — |
| 22/F | Osteosarcoma | Radiation 50 Gy MTX, CPA, DXR | 17 | AML (M4) | 46, XX, inv(16)(p13q22) | WT | — |
| Age/ sex . | Primary disease . | Therapy . | Latent period (mo) . | Secondary disease . | Chromosome . | AML1 mutation . | Case no. . |
|---|---|---|---|---|---|---|---|
| 39/F | Astrocytoma | Radiation 124 Gy MCNU, ACNU, CPA, DXR | 152 | MDS (RAEBt) | 46, XX | 530G>A Arg177Gln | 9 |
| 62/M | B-cell lymphoma3-150 | Radiation 39.6 Gy CPA, DXR, VCR, PSL, VP16, MIT | 74 | AML (M0) | 46, XY | 413_414insCGGGGG Gly138_Arg139insGlyGly | 10 |
| 72/F | Uteric cancer | Carboplatin, PSL | 22 | MDS (RAEB) | 45, XX, −5, t(12;21)(q24;q22) | WT | — |
| 56/F | Breast cancer | 5-FU, CPA, MTX | 31 | AML (M3) | 46, XX, t(15;17)(q22;q21) | WT | — |
| 52/F | Breast cancer | Radiation 45 Gy | 18 | AML (M2) | 46, XX, t(8;21)(q22;q22) | WT | — |
| 22/F | Osteosarcoma | Radiation 50 Gy MTX, CPA, DXR | 17 | AML (M4) | 46, XX, inv(16)(p13q22) | WT | — |
MCNU indicates ranimustine; ACNU, nimustine hydrochloride; CPA, cyclophosphamide; DXR, doxorubicin hydrochloride; VCR, vincristine sulfate; PSL, prednisolone; VP16, etoposide; MIT, mitoxantrone hydrochloride; 5-FU, fluorouracil; MTX, methotrexate; and —, case number not assigned.
This patient had exposed atomic bomb at a point 4.0 kilometers from the hypocenter.